AbbVie Says “V” Is For V-Shaped Recovery
Q2 Victories Include Botox Rebound, Big Skyrizi, Rinvoq Gains
Executive Summary
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.
You may also be interested in...
AbbVie’s Q1 Revenue Growth Outpaces Big Pharma Peers
Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.
Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.